,i #aafth ,,congress #b;d ,session ,h4 ,r4 #ggja ,,in ,,the ,,house ,,of ,,representatives ,july #ba1 #bjbj,mr4 ,cartwright introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committees on the ,judiciary1 ,education and ,labor1 and ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to establish programs related to prevention of prescription opioid misuse1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,addiction ,prevention and ,responsible ,opioid ,practices ,act4 #b4 ,federal licensure of pharmaceutical representatives who promote certain opioids ,subchapter ,e of chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;bbb et seq47 is amended by adding at the end the following3 #efi;,e4 ,federal licensure of pharmaceutical representatives who promote certain opioids 7a7 ,in general ,the ,secretary1 in consultation with the ,attorney ,general1 shall establish a licensure program for pharmaceutical representatives described in subsection 7b74 7b7 ,licensure program 7#a7 ,requirement ,beginning on ,july #a1 #bjba1 no individual described in paragraph 7#b7 may engage in the marketing or promoting of opioid drugs unless such individual is licensed under this section4 7#b7 ,individuals required to obtain licensure ,an individual required to obtain a license under this section is any individual who1 on behalf of a drug manufacturer1 engaged1 on more than #ae days in a calendar year1 in the marketing or promotion to health care professionals1 including educational or sales communications1 meetings or paid events1 and the provision of goods1 gifts1 and samples1 of any opioid drug 7other than methadone7 that is listed in schedule ,,ii of section #bjb7;c7 of the ,controlled ,substances ,act4 7#c7 ,licensure period ,each license issued under this section shall be valid for #c years1 and may be renewed for additional #c-year periods4 7c7 ,requirements ,an individual required to obtain a license under this section shall-- 7#a7 submit to the ,secretary1 at such time and in such manner as the ,secretary may require-- 7,a7 such information as the ,secretary may require2 and 7,b7 a registration fee in the amount of #c1jjj2 7#b7 certify that such individual has completed training on ethics1 pharmaceutical marketing regulations1 the ,,cdc ,guidelines for ,prescribing ,opioids for ,chronic ,pain1 published by the ,centers for ,disease ,control and ,prevention in #bjaf 7or any successor document7 or the ,,fda ,blueprint for ,prescriber ,education for ,extended-,release and ,long-,acting ,opioid ,analgesics1 and applicable ,federal laws pertaining to drug marketing1 labeling1 and clinical trials1 as the ,secretary may require2 7#c7 certify that such individual will not engage in any illegal1 fraudulent1 misleading1 or other deceptive marketing of schedule ,,ii opioid drugs2 and 7#d7 file with the ,secretary annual reports disclosing the names of providers visited and any drug samples or gifts such individual gives any such provider4 7d7 ,manufacturer reporting requirements ,the manufacturer who employs or contracts with any individual required to obtain a license under this section shall include in reports required under section #aabh;,g of the ,social ,security ,act the name of each such licensed individual that provides payments or other transfers of value required to be reported under such section #aabh;,g that relates to an opioid drug that is listed in schedule ,,ii of the ,controlled ,substances ,act4 4 #c4 ,withdrawal of approval of certain opioids 7a7 ,in general ,notwithstanding any other provision of law1 any ultra-high-dose opioid shall be considered a drug that presents an imminent hazard to the public health within the meaning of section #eje7;e7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;e771 and the ,secretary of ,health and ,human ,services shall suspend the approval of such drug1 in accordance with such section #eje7;e74 7b7 ,definition ,in this section1 the term ultra-high-dose opioid means an opioid drug for which the daily dosage provided for in the approved label exceeds the morphine milligram equivalents per day outlined in the report entitled ,,cdc ,guidelines for ,prescribing ,opioids for ,chronic ,pain1 published by the ,centers for ,disease ,control and ,prevention in #bjaf 7or any successor document74 #d4 ,continuing medical education and prescription drug monitoring program registration for prescribers ,section #cjc of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbc7 is amended-- 7#a7 by redesignating subsection 7k7 as subsection 7l72 and 7#b7 by inserting after subsection 7j7 the following3 7k7 7#a7 ,the ,attorney ,general shall not register1 or renew the registration of1 a practitioner under subsection 7f7 who is licensed under ,state law to prescribe controlled substances in schedule ,,ii1 ,,iii1 or ,,iv1 unless the practitioner submits to the ,attorney ,general1 for each such registration or renewal request1 a written certification that-- 7,a7 7i7 the practitioner has1 during the #a-year period preceding the registration or renewal request1 completed a training program described in paragraph 7#b72 or 7ii7 the practitioner1 during the applicable registration period1 will not prescribe such controlled substances in amounts in excess of a #gb-;hour supply 7for which no refill is available72 and 7,b7 the practitioner has registered with the prescription drug monitoring program of the ,state in which the practitioner practices1 if the ,state has such program4 7#b7 ,a training program described in this paragraph is a training program that-- 7,a7 follows the best practices for pain management1 as described in the ,guideline for ,prescribing ,opioids for ,chronic ,pain as published by the ,centers for ,disease ,control and ,prevention in #bjaf1 or any successor thereto1 or the ,,fda ,blueprint for ,prescriber ,education for ,extended-,release and ,long-,acting ,opioid ,analgesics as published by the ,food and ,drug ,administration in #bjag1 or any successor thereto2 7,b7 includes information on-- 7i7 recommending non-opioid and non-pharmacological therapy2 7ii7 establishing treatment goals and evaluating patient risks2 7iii7 prescribing the lowest dose and fewest number of pills considered effective2 7iv7 addictive and overdose risks of opioids2 7v7 diagnosing and managing substance use disorders1 including linking patients to evidence-based treatment2 7vi7 identifying narcotics-seeking behaviors2 and 7vii7 using prescription drug monitoring programs2 and 7,c7 is approved by the ,secretary4 4 #e4 ,report on prescriber education courses for medical and dental students ,each school of medicine1 school of osteopathic medicine1 and school of dentistry participating in a program under title ,,iv of the ,higher ,education ,act of #aife 7#bj ,u4,s4,c4 #ajgj;a et seq471 as a condition for such participation1 shall submit an annual report to the ,secretary of ,education and the ,secretary of ,health and ,human ,services on any prescriber education courses focused specifically on pain management and responsible opioid prescribing practices that such school requires students to take1 and whether such courses are consistent with the most recently published version of the ,guideline for ,prescribing ,opioids for ,chronic ,pain of the ,centers for ,disease ,control and ,prevention or the ,,fda ,blueprint for ,prescriber ,education for ,extended-,release and ,long-,acting ,opioid ,analgesics1 as published by the ,food and ,drug ,administration in #bjag4 ,the ,secretary of ,education and the ,secretary of ,health and ,human ,services shall compile the reports submitted by such schools and submit an annual summary of such reports to ,congress4 #f4 ,requirements under ,prescription ,drug ,monitoring ,programs 7a7 ,in general ,beginning #a year after the date of enactment of this ,act1 each ,state that receives funding under any of the programs described in subsection 7c7 shall-- 7#a7 require practitioners1 or their designees1 in the ,state to consult the database of the prescription drug monitoring program before writing prescriptions for controlled substances 7as such term is defined in section #ajb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hjb77 in schedule ,,ii1 ,,iii1 or ,,iv under section #bjb of such ,act 7#ba ,u4,s4,c4 #hab72 7#b7 require dispensers of controlled substances in schedule ,,ii1 ,,iii1 or ,,iv1 or their designees1 to input data into the database of the prescription drug monitoring program within #bd hours of filling a qualifying prescription1 as required by the ,attorney ,general and the ,secretary of ,health and ,human ,services1 including patient identifier information1 the national drug code of the dispensed drug1 date of dispensing the drug1 quantity and dosage of the drug dispensed1 form of payment1 ,drug ,enforcement ,administration registration number of the practitioner1 ,drug ,enforcement ,administration registration number of the dispenser2 7#c7 allow practitioners and dispensers to designate other appropriate individuals to act as agents of such practitioners and dispensers for purposes of obtaining and inputing data from the database for purposes of complying with paragraphs 7#a7 and 7#b71 as applicable2 7#d7 provide informational materials for practitioners and dispensers to identify and refer patients with possible substance use disorders to professional treatment specialists2 7#e7 establish formal data sharing agreements to foster electronic connectivity with the prescription drug monitoring programs of each ,state 7if such ,state has such a program7 with which the ,state shares a border1 to facilitate the exchange of information through an established technology architecture that ensures common data standards1 privacy protection1 and secure and streamlined information sharing2 7#f7 authorize direct access to the ,state's database of the prescription drug monitoring program to all ,state law enforcement agencies1 ,state boards responsible for the licensure1 regulation1 or discipline of practitioners1 pharmacists1 or other persons authorized to prescribe1 administer1 or dispense controlled substances2 and 7#g7 in order to enhance accountability in prescribing and dispensing patterns1 not fewer than #d times per year1 proactively provide informational reports on aggregate trends and individual outliers1 based on information available through the ,state prescription drug monitoring program to-- 7,a7 the ,state entities and persons described in paragraph 7#f72 and 7,b7 the ,medicaid agency and the department of public health of the ,state4 7b7 ,transparency in ,prescribing ,practices and ,intervention for ,high ,prescribers 7#a7 ,state reporting requirement ,each ,state that receives funding under any of the programs described in subsection 7c7 shall1 twice per year1 submit to the ,secretary of ,health and ,human ,services and the ,administrator of the ,drug ,enforcement ,administration-- 7,a7 a list of all practitioners and dispensers who1 in the applicable reporting period1 have prescribed or dispensed schedule ,,ii1 ,,iii1 or ,,iv opioids in the ,state2 7,b7 the amount of schedule ,,ii1 ,,iii1 or ,,iv opioids that were prescribed and dispensed by each individual practitioner and dispenser described in subparagraph 7,a72 and 7,c7 any additional information that the ,secretary and ,administrator may require to support surveillance and evaluation of trends in prescribing or dispensing of schedule ,,ii1 ,,iii1 or ,,iv opioids1 or to identify possible non-medical use and diversion of such substances4 7#b7 ,annual report ,not later than #a year after the date of enactment of this ,act1 and annually thereafter1 the ,secretary of ,health and ,human ,services1 in consultation with the ,administrator of the ,drug ,enforcement ,administration1 the ,secretary of ,defense1 the ,secretary of ,veterans ,affairs1 and the ,director of the ,indian ,health ,service1 shall submit to ,congress1 and make public1 a report identifying outliers among the medical specialties and geographic areas with the highest rates of opioid prescribing in the ,nation1 by zip code4 7#c7 ,development of action plan 7,a7 ,initial plan ,not later than #a year after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services1 in consultation with the ,administrator of the ,drug ,enforcement ,administration1 the ,secretary of ,defense1 the ,secretary of ,veterans ,affairs1 and the ,director of the ,indian ,health ,service1 shall submit to ,congress a plan of action1 including warning letters and enforcement mechanisms1 for addressing outliers in opioid prescribing practices and ensuring an adequate ,federal response to protect the public health4 7,b7 ,updated plan ,the ,secretary of ,health and ,human ,services shall submit to ,congress updates to the plan of action described in subparagraph 7,a71 as such ,secretary1 in consultation with the heads of agencies described in such subparagraph1 determines appropriate4 7c7 ,programs described ,the programs described in this subsection are-- 7#a7 the ,harold ,rogers ,prescription ,drug ,monitoring ,program established under the ,departments of ,commerce1 ,justice1 and ,state1 the ,judiciary1 and ,related ,agencies ,appropriations ,act1 #bjjb 7,public ,law #ajg-gg2 #aae ,stat4 #gdh72 7#b7 the controlled substance monitoring program under section #cii,o of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bhj;g-#c72 7#c7 the ,prescription ,drug ,overdose3 ,prevention for ,states program of the ,centers for ,disease ,control and ,prevention2 7#d7 the ,prescription ,drug ,overdose3 ,data-,driven ,prevention ,initiative of ,centers for ,disease ,control and ,prevention2 7#e7 the ,enhanced ,state ,opioid ,overdose ,surveillance program of the ,centers for ,disease ,control and ,prevention2 7#f7 the opioid grant program under section #ajjc of the #bast ,century ,cures ,act 7,public ,law #aad-bee72 and 7#g7 the ,state ,opioid ,response ,grant program described under the heading ,substance abuse treatment under the heading ,substance abuse and mental health services administration of title ,,ii of division ,a of the ,further ,consolidated ,appropriations ,act1 #bjbj 7,public ,law #aaf-id74 7d7 ,definitions ,in this section1 the terms dispenser and practitioner have the meanings given such terms in section #ajb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hjb74 #g4 ,interoperability of certified health information technology ,section #cjja7;c77#e7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;jj-#aa7;c77#e77 is amended by adding at the end the following3 7,f7 ,interoperability ,beginning on ,january #a1 #bjba1 the ,national ,coordinator shall not certify electronic health records as health information technology that is in compliance with applicable certification criteria under this paragraph unless such technology is interoperable with the prescription drug monitoring programs of each ,state that1 at the time of the request for such certification1 has such a program4 4 #h4 ,studies related to overdose discharge and follow-up policies 7a7 ,study ,not later than ,january #a1 #bjba1 the ,secretary of ,health and ,human ,services shall-- 7#a7 conduct a study on the scope and circumstances of non-fatal opioid overdoses1 the policies and procedures that ,states1 health care systems1 and first responders have implemented2 and 7#b7 in partnership with stakeholder organizations with subject matter expertise1 establish guidelines for hospital procedures following non-fatal opioid overdose and the administration of overdose reversal medication4 7b7 ,study and development of quality measures under ,medicare related to opioid abuse and substance use disorder ,section #ahij;,a7e7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acie;aaa-#a7;e77 is amended-- 7#a7 by striking measures4--,the ,administrator and inserting 8measures4-- 7#a7 ,in general ,the ,administrator 2 and 7#b7 by adding at the end the following new paragraph3 7#b7 ,study and development of quality measures related to opioid abuse and substance use disorder ,beginning not later than #a year after the date of enactment of this paragraph1 the ,administrator of the ,center for ,medicare ,medicaid ,services shall study1 and through contracts develop1 in coordination with appropriate subject matter organizations 7such as the entity with a contract under section #ahij71 for use under this ,act1 quality measures related to standards of care for treating individuals with non-fatal opioid overdose1 discharge procedures1 and linkages to appropriate substance use disorder treatment and community support services4 4 #i4 ,medicaid opioid drug mapping tool 7a7 ,in general ,the ,secretary of ,health and ,human ,services shall create an interactive opioid drug mapping tool1 which shall be made publicly available on the internet website of the ,centers for ,medicare ,medicaid ,services1 showing prescribing practices of providers that participate in ,state ,medicaid programs and geographic comparisons1 at the ,state1 county1 and ,,zip code levels1 of de-identified opioid prescription claims made under ,state ,medicaid programs under title ,,xix of the ,social ,security ,act 7#db ,u4,s4,c4 #acif et seq474 7b7 ,collection of data from ,states ,the ,secretary of ,health and ,human ,services may request from ,states such data as the ,secretary determines necessary to create the opioid mapping tool described in subsection 7a74 #aj4 ,national ,academies study 7a7 ,study ,the ,secretary of ,health and ,human ,services shall enter into a contract with the ,national ,academies of ,science1 ,engineering1 and ,medicine 7referred to in this section as the ,national ,academies7 to carry out a study on the addition of coverage under the ,medicare program under title ,,xviii of the ,social ,security ,act of alternative treatment modalities 7such as integrative medicine1 including acupuncture and exercise therapy1 neural stimulation1 biofeedback1 radiofrequency ablation1 and trigger point injections7 furnished to ,medicare beneficiaries who suffer from acute or chronic lower back pain4 ,such study shall1 pursuant to the contract under this paragraph1 include an analysis of-- 7#a7 scientific research on the short-term and long-term impact of the addition of such coverage on clinical efficacy for pain management of such beneficiaries2 7#b7 whether the lack of ,medicare coverage for alternative treatment modalities impacts the volume of opioids prescribed for beneficiaries2 and 7#c7 the cost to the ,medicare program of the addition of such coverage to treat pain and mitigate the progression of chronic pain1 as weighed against the cost of opioid use disorder1 overdose1 readmission1 subsequent surgeries1 and utilization and expenditures under parts ,b and ,d of such title4 7b7 ,report ,not later than #a year after the date of enactment of this ,act1 pursuant to the contract under subsection 7a71 the ,national ,academies shall submit to ,congress a report on the study under subsection 7a74 7c7 ,authorization of appropriations ,to carry out this section1 there are authorized to be appropriated such sums as may be necessary4 #aa4 ,excise tax on opioid pain relievers 7a7 ,in general ,subchapter ,e of chapter #cb of the ,internal ,revenue ,code of #aihf is amended by adding at the end the following new section3 #daib4 ,opioid pain relievers 7a7 ,in general ,there is hereby imposed on the manufacturer or producer of any taxable active opioid a tax equal to the amount determined under subsection 7b74 7b7 ,amount determined ,the amount determined under this subsection with respect to a manufacturer or producer for a calendar year is #a cent per milligram of taxable active opioid in the production or manufacturing quota determined for such manufacturer or producer for the calendar year under section #cjf of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbf74 7c7 ,taxable active opioid ,for purposes of this section-- 7#a7 ,in general ,the term taxable active opioid means any controlled substance 7as defined in section #ajb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hjb71 as in effect on the date of the enactment of this section7 manufactured in the ,united ,states which is opium1 an opiate1 or any derivative thereof4 7#b7 ,exclusions 7,a7 ,other ingredients ,in the case of a product that includes a taxable active opioid and another ingredient1 subsection 7a7 shall apply only to the portion of such product that is a taxable active opioid4 7,b7 ,drugs used in addiction treatment ,the term taxable active opioid shall not include any controlled substance 7as so defined7 which is used exclusively for the treatment of opioid addiction as part of a medication-assisted treatment4 4 7b7 ,clerical amendments 7#a7 ,the heading of subchapter ,e of chapter #cb of the ,internal ,revenue ,code of #aihf is amended by striking ,medical devices and inserting ,other medical products4 7#b7 ,the table of subchapters for chapter #cb of such ,code is amended by striking the item relating to subchapter ,e and inserting the following new item3 ,subchapter ,e4 ,other medical products 4 7#c7 ,the table of sections for subchapter ,e of chapter #cb of such ,code is amended by adding at the end the following new item3 ,sec4 #daib4 ,opioid pain relievers4 4 7c7 ,effective date ,the amendments made by this section shall apply to calendar years beginning after the date of the enactment of this ,act4 #ab4 ,opioid consumer abuse reduction program 7a7 ,opioid take-,back program ,section #cjb of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbb7 is amended by adding at the end the following3 7h7 7#a7 ,the ,attorney ,general shall establish a national take-back program for the safe and environmentally responsible disposal of controlled substances4 7#b7 ,in establishing the take-back program required under paragraph 7#a71 the ,attorney ,general-- 7,a7 shall consult with the ,secretary and the ,administrator of the ,environmental ,protection ,agency2 and 7,b7 may coordinate with ,states1 law enforcement agencies1 water resource management agencies1 manufacturers1 practitioners1 pharmacists1 public health entities1 transportation and incineration service contractors1 and other entities and individuals1 as appropriate4 7#c7 ,the take-back program established under paragraph 7#a7-- 7,a7 shall-- 7i7 ensure appropriate geographic distribution so as to provide-- 7,i7 reasonably convenient and equitable access to permanent take-back locations1 including not less than #a disposal site for every #be1jjj residents and not less than #a physical disposal site per town1 city1 county1 or other unit of local government1 where possible2 and 7,,ii7 periodic collection events and mail-back programs1 including public notice of such events and programs1 as a supplement to the permanent take-back locations described in subclause 7,i71 particularly in areas in which the provision of access to such locations at the level described in that subclause is not possible2 7ii7 establish a process for the accurate cataloguing and reporting of the quantities of controlled substances collected2 and 7iii7 include a public awareness campaign and education of practitioners and pharmacists2 and 7,b7 may work in coordination with ,state and locally implemented public and private take-back programs4 7#d7 ,from time to time1 beginning in the second calendar year that begins after the date of enactment of this subsection1 the ,secretary of the ,treasury shall transfer from the general fund of the ,treasury an amount equal to one-half of the total amount of taxes collected under section #daib of the ,internal ,revenue ,code of #aihf to the ,attorney ,general to carry out this subsection4 ,amounts transferred under this subparagraph shall remain available until expended4 4 7b7 ,funding of substance abuse programs ,from time to time1 beginning in the second calendar year that begins after the date of enactment of this ,act1 the ,secretary of the ,treasury shall transfer from the general fund of the ,treasury an amount equal to one-half of the total amount of taxes collected under section #daib of the ,internal ,revenue ,code of #aihf1 as added by this ,act1 to the ,director of the ,center for ,substance ,abuse ,treatment of the ,substance ,abuse and ,mental ,health ,services ,administration for programs of the ,center1 including the ,block ,grants for ,prevention and ,treatment of ,substance ,abuse program under subpart ,,ii of part ,b of title ,,xix of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjjx-#ba et seq47 and ,programs of ,regional and ,national ,significance4 ,amounts transferred under this subsection shall remain available until expended4 #ac4 ,,gao study ,not later than #a year after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall-- 7#a7 conduct a study examining the coverage offered under commercial health insurance plans and reimbursement rates under the ,medicare program and ,state ,medicaid plans with respect to-- 7,a7 substance use disorder treatment services1 as compared to other health services1 and how any disparity identified under this paragraph may contribute to differences in salary and turnover among substance abuse disorder providers2 and 7,b7 rates of coverage or reimbursement1 as applicable1 for substance abuse disorder services provided via telehealth1 as compared to such services provided in-person2 and 7#b7 provide recommendations with respect to addressing any disparities identified under subparagraph 7,a7 or 7,b7 of paragraph 7#a7 in order to bolster retention of substance abuse disorder providers and the provision of substance abuse disorder services4 #ad4 ,expanding access to substance use disorder and mental health services furnished through telehealth under the ,medicare program ,section #ahcd7m77#g7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciem7m77#g77 is amended-- 7#a7 in the paragraph heading1 by inserting and mental health services after substance use disorder services2 7#b7 by inserting or1 on or after the first day after the end of the public health emergency described in section #aace7;g77#a77;,b71 to an eligible telehealth individual for purposes of diagnosis of a substance use disorder or diagnosis or treatment of a mental health disorder1 as determined by the ,secretary1 after as determined by the ,secretary14 #ae4 ,ensuring parity for mental health and addiction treatment services ,title ,v of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bijll et seq47 is amended-- 7#a7 in part ,k1 by redesignating section #eej 7#db ,u4,s4,c4 #bij;ee-#aj71 relating to sobriety treatment and recovery teams1 as section #eec and transferring such section to appear after section #eeb in part ,d2 and 7#b7 by adding at the end of such part ,d the following3 #eed4 ,compliance with mental health and addiction treatment parity 7a7 ,in general ,the ,secretary1 in coordination with the ,secretary of ,labor1 shall award grants to1 or enter into cooperative agreements with1 ,states to ensure that health insurance issuers in the ,state comply with section #bgbf4 7b7 ,use of grant ,a ,state shall use amounts received under a grant or cooperative agreement under this section to-- 7#a7 establish clear guidelines for parity compliance for mental health and substance use disorder benefits2 7#b7 ensure parity compliance during public health emergencies with best practices for delivering evidence-based mental health and substance use disorder treatment1 including to ensure virtual1 video1 internet1 telephonic1 and other remote services are appropriately covered1 including alignment with authorities1 flexibilities1 and coverage promulgated by the ,centers for ,medicare ,medicaid ,services2 7#c7 engage with health insurance issuers to ensure that they comply with the guidelines promulgated and other provisions of section #bgbf1 including through audits1 market conduct examinations1 secret shopper programs1 or other means2 7#d7 share information with other ,states who receive grants under this section2 7#e7 submit a report to the ,secretary and the ,secretary of ,labor on information1 actions1 recommendations1 and such other information as such secretaries may require2 and 7#f7 publicly post a summary of each report submitted under paragraph 7#e7 on the websites of the ,department of ,health and ,human ,services and the ,department of ,labor4 7c7 ,authorization of appropriations ,there are authorized to be appropriated to carry out this section #aj1jjj1jjj for each of fiscal years #bjba through #bjbe4 4